So far, the Food and Drug Administration has approved 7 antagonistic monoclonal antibodies (mAbs) against cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell-death protein-1 (PD-1), and its ligand PD-L1 for treatment of cancer (2). Here, CTLA4 is linked to cancer.